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Summary
The MUC1 transforming protein is overexpressed by most human carcinomas. The present studies demonstrate that the
MUC1 C-terminal subunit (MUC1 C-ter) localizes to mitochondria in HCT116/MUC1 colon carcinoma cells and that heregulin
stimulates mitochondrial targeting of MUC1 C-ter. We also show that MUC1 attenuates cisplatin-induced (1) release of
mitochondrial apoptogenic factors, (2) activation of caspase-3, and (3) induction of apoptosis. Moreover, knockdown of
MUC1 expression in A549 lung and ZR-75-1 breast carcinoma cells by MUC1siRNA was associated with increased sensitivity
to genotoxic drugs in vitro and in vivo. These findings indicate that MUC1 attenuates the apoptotic response to DNA
damage and that this oncoprotein confers resistance to genotoxic anticancer agents.
Introduction The human DF3/MUC1 transmembrane glycoprotein is ex-
pressed on the apical borders of normal secretory epithelial
The apoptotic response of cells is induced by extrinsic and cells (Kufe et al., 1984). By contrast, transformation of epithelia
intrinsic pathways that activate the caspase family of cysteine to carcinomas is associated with marked overexpression of
proteases. The extrinsic apoptotic pathway is activated by li- MUC1 throughout the entire cell membrane (Kufe et al., 1984).
gand stimulation of the tumor necrosis factor (TNF) family of MUC1 is expressed as a cell surface heterodimer that consists
death receptors. Activation of caspase-8 by death receptor sig- of N-terminal (N-ter) and C-terminal (C-ter) subunits, which form
naling results in cleavage of procaspase-3 (Boldin et al., 1996; a stable complex following cleavage of a single MUC1 polypep-
Muzio et al., 1996; Stennicke et al., 1998). Caspase-8 also tide in the endoplasmic reticulum (ER) (Ligtenberg et al., 1992).
cleaves Bid, a proapoptotic member of the Bcl-2 family, and The 250 kDa N-ter ectodomain contains variable numbers of
thereby stimulates release of mitochondrial cytochrome c to the 20 amino acid tandem repeats that are extensively modified by
cytosol (Li et al., 1998a; Luo et al., 1998). Activation of the O-linked glycans (Gendler et al., 1988; Siddiqui et al., 1988).
intrinsic pathway by diverse Bid-independent stress signals is The 20–25 kDa C-ter, which anchors the N-ter to the cell
also associated with the release of mitochondrial cytochrome c surface, consists of a 58 amino acid extracellular region, a 28
(Kluck et al., 1997; Liu et al., 1996; Yang et al., 1997). In the
amino acid transmembrane domain, and a 72 amino acid cyto-
cytosol, cytochrome c forms a complex with Apaf-1 and acti-
plasmic domain (CD) (Merlo et al., 1989). The MUC1-CD isvates caspase-9 (Li et al., 1997; Srinivasula et al., 1998). Like
phosphorylated on Y-46 by the epidermal growth factor receptorcaspase-8, caspase-9 can directly activate caspase-3 (Li et al.,
(EGFR), c-Src (Li et al., 2001a, 2001b), and Lyn (Li et al., 2003a).1997). In turn, caspase-3 cleaves multiple proteins, which, when
Other studies have shown that MUC1-CD is phosphorylated oninactivated or activated by cleavage, contribute to the induction
S-44 by glycogen synthase kinase 3 (GSK3) (Li et al., 1998b)of apoptosis. Protein kinase C (PKC) is one such caspase-3
and on T-41 by PKC (Ren et al., 2002). Phosphorylation on Y-46substrate that is cleaved to a catalytically active fragment, the
and T-41 induces binding of MUC1-CD with the Wnt effectorexpression of which is sufficient to induce apoptosis (Emoto et
-catenin (Li et al., 2001a, 2001b; Ren et al., 2002). Conversely,al., 1995). Many genotoxic anticancer drugs induce apoptosis
GSK3-mediated phosphorylation of S-44 decreases the inter-by activation of the intrinsic pathway (Herr and Debatin, 2001;
action of MUC1-CD and -catenin (Li et al., 1998b). TheseKroemer and Reed, 2000). Moreover, resistance to cytotoxic
findings have indicated that MUC1-CD functions in integratinganticancer agents is often associated with defects in the intrinsic
pathway (Bunz, 2001; Datta et al., 1995). signals from the EGFR and Wnt pathways.
S I G N I F I C A N C E
The human MUC1 transmembrane glycoprotein is aberrantly overexpressed in about 800,000 of the 1.3 million tumors diagnosed in
the U.S. each year. MUC1 interacts with the ErbB and Wnt signaling pathways and induces transformation. The present studies
demonstrate that MUC1 localizes to mitochondria and that MUC1 blocks activation of the intrinsic apoptotic pathway by genotoxic
agents. The results also demonstrate that MUC1 confers resistance to treatment in animal tumor models. These findings indicate that
overexpression of MUC1 in human tumors could be of importance to the effectiveness of anticancer therapy.
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Overexpression of MUC1 confers anchorage-independent clear localization of MUC1 C-ter at the cell membrane (Figure
1D, upper panels) and with MitoTracker throughout the mito-growth and tumorigenicity of rodent fibroblasts and human epi-
thelial cells (Li et al., 2003c; Ren et al., 2002). Other work has chondrial network (Figure 1D, lower panels). Of note, detection
of MUC1 C-ter at the cell membrane is obscured when focusingshown that, in addition to localization at the cell membrane, the
MUC1 C-ter is expressed in nuclear complexes with -catenin the confocal images on mitochondria (Figure 1D, lower panels).
Moreover, within the cell, MUC1 C-ter expression is not re-(Li et al., 2003a, 2003b, 2003c; Wen et al., 2003). Moreover,
treatment of cells with heregulin (HRG), which activates stricted to mitochondria and, in addition to colocalization with
MitoTracker, is detectable in the ER and cytosol (Figure 1D).ErbB2-4, is associated with targeting of MUC1 C-ter to the
nucleus in a complex with -catenin (Li et al., 2003c). These To confirm these findings, mitochondrial lysates from the
transfectants were subjected to immunoblot analysis with anti-observations have indicated that the function of MUC1 as a
transforming protein may be mediated by regulating gene ex- MUC1 C-ter. The results demonstrate that the C-ter is detect-
able in the mitochondrial fraction from HCT116/MUC1, but notpression. In the present studies, we show that the MUC1 C-ter
localizes to mitochondria. Significantly, the results demonstrate from HCT116/vector, cells (Figure 1E). Moreover, in concert with
the confocal data, mitochondrial localization of the MUC1(Y46F)that MUC1 blocks activation of the intrinsic apoptotic pathway
by DNA damaging agents. Our findings indicate that overexpres- C-ter was considerably less than that found for the MUC1 C-ter
(Figure 1E). Equal loading of mitochondrial lysates was con-sion of MUC1 by human carcinomas contributes to the resis-
tance of these cells to genotoxic agents. firmed by immunoblotting for the mitochondrial HSP60 protein
(Figure 1E). Absence of the MUC1 N-ter indicated that the mito-
chondrial fraction was not contaminated with cell membranesResults
(Figure 1E). Immunoblot analysis of the mitochondrial lysates
with antibodies against the cytosolic IB, nuclear PCNA, andMUC1 C-ter localizes to mitochondria
MUC1-negative HCT116 cells were transfected to stably ex- ER-associated calreticulin proteins further indicated that the
mitochondria are not significantly contaminated with these sub-press the empty vector, MUC1, or the MUC1(Y46F) mutant.
Two clones (A and B) of each were selected from independent cellular fractions (Figure 1E).
transfections. Immunoblot analysis with anti-MUC1 demon-
strated no detectable expression of the MUC1 N-ter or C-ter Targeting of MUC1 C-ter to mitochondria
is associated with HRG treatmentsubunits in the vector transfectants (Figure 1A). By contrast,
MUC1 N-ter expression was similar in cells transfected with To compare MUC1 C-ter expression at the cell membrane with
that in mitochondria, lysates from these fractions were sub-MUC1 or MUC1(Y46F) (Figure 1A). Similar levels of MUC1 C-ter
were also found in the MUC1 and MUC1(Y46F) transfectants jected to immunoblot analysis with antibodies directed against
the extracellular domain (ECD) and cytoplasmic domain (CD)(Figure 1A). To assess whether MUC1 is expressed at the cell
membrane, the transfectants were analyzed by flow cytometry (Figure 2A, upper panel). The results obtained with the Ab5
antibody, which reacts with the C-terminal 17 amino acids ofwith the anti-MUC1 N-ter antibody. In contrast to HCT116/
vector cells, MUC1 was detectable on the surface of HCT116 MUC1 CD, demonstrated similar patterns for MUC1 C-ter ex-
pressed at the cell membrane and in mitochondria (Figure 2A).cells expressing MUC1 or MUC1(Y46F) (Figure 1B). To further
define the distribution of MUC1, confocal microscopy was per- Reactivity with Ab5 was observed predominantly at 20–25 kDa
(Figure 2A). Reactive bands were also observed at 17 and 15formed with antibodies against the MUC1 N-ter and C-ter. Both
subunits were detectable at the cell membrane of the MUC1 kDa (Figure 2A). Immunoblotting with the DF3E antibody, which
was generated against the VETQFNQYKTEAAS motif in thetransfectants (Figure 1C). Unexpectedly, however, the MUC1
C-ter, and not the N-ter, was also expressed in a pattern that MUC1 ECD (Li et al., 2001a), demonstrated reactivity with ly-
sates from both the cell membrane and mitochondria (Figuresuggested mitochondrial localization (Figure 1C). Indeed, colo-
calization of the MUC1 C-ter and MitoTracker supported tar- 2A). Notably, reactivity of the DF3E antibody with the 20–25
kDa MUC1 C-ter and the 17 kDa fragment indicates that thegeting of MUC1 C-ter to mitochondria (Figure 1C). By contrast,
there was substantially less mitochondrial localization of the 15 kDa fragment, as detected with Ab5, does not contain the
DF3E epitope (Figure 2A). Another antibody generated againstMUC1(Y46F) C-ter (Figure 1C). Higher magnification and focus-
ing of the images within a single HCT116/MUC1 cell showed the MUC1 ECD, designated ECD1, reacted predominantly with
Figure 1. MUC1 C-ter localizes to mitochondria
HCT116 cells were transfected to stably express the empty vector, MUC1, or MUC1(Y46F). Clones (A and B) were selected from two independent transfections.
A: Lysates were subjected to immunoblot analysis with anti-MUC1 N-ter (DF3), anti-MUC1 C-ter (Ab5), and anti--actin.
B: Cells were incubated with anti-MUC1 N-ter (open patterns) or control mouse IgG (closed patterns) and analyzed for immunofluorescence by flow
cytometry.
C: Confocal microscopy of HCT116/Vector-A, HCT116/MUC1-A, and HCT116/MUC1(Y46F)-A cells stained with anti-MUC1 N-ter (DF3) or C-ter (Ab5). Mitochon-
dria were stained with MitoTracker Red. Nuclei were stained with TO-PRO-3. Scale bars represent 20 m in the upper three panels and 10 m in the lower
panel.
D: Higher magnification of an HCT116/MUC1-A cell stained with anti-MUC1 C-ter (Ab5), Mitotracker Red CMXRos, and TO-PRO-3. Confocal images were
focused on cell membrane (upper panels) and mitochondrial (lower panels) staining with anti-MUC1 C-ter. Scale bars represent 10 m.
E: Mitochondrial fractions from HCT116/vector-A, HCT116/MUC1-A, and HCT116/MUC1(Y46F)-A cells were subjected to SDS-PAGE and immunoblotting with
the indicated antibodies. Whole-cell lysate (WCL) was included as a control for detection of the membrane-associated MUC1 N-ter, cytoplasmic IB,
nuclear PCNA, and endoplasmic reticulum-associated calreticulin proteins.
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Figure 2. HRG stimulation targets MUC1 C-ter to mitochondria
A: Schematic representation of MUC1 C-ter with sites recognized by the indicated antibodies (upper panel). Lysates from the cell membrane (CM) and
mitochondrial (Mito) fractions of HCT116/MUC1-A cells were subjected to SDS-PAGE and immunoblot analysis with the indicated antibodies (lower panels).
B: Purified mitochondria (0.4 mg protein/ml) were treated with 0, 50, or 100 g/ml trypsin for 20 min at 4C (left). The samples were subjected to immunoblot
analysis with the indicated antibodies. Purified mitochondria (0.4 mg protein/ml) were resuspended in 0.1 M Na2CO3 (pH 11.5), incubated for 30 min at
0C, and then centrifuged at 100,000 	 g for 30 min at 4C (right). The supernatant (S) and pellet (P) were analyzed by immunoblotting with the indicated
antibodies.
C: HCT116 cells were transiently transfected with MUC1 C-ter tagged at the N terminus with GFP (GFP-MUC1 C-ter) and harvested at 36 hr. Lysates from
cell membrane (CM) and mitochondrial (Mito) fractions were subjected to immunoblot analysis with the indicated antibodies (left). Whole-cell lysate (WCL)
was included as a control. Confocal microscopy was performed on the transfected HCT116 cells after staining with MitoTracker Red and TO-PRO-3. Scale
bars represent 10 m.
D: HCT116/MUC1 and HCT116/MUC1(Y46F) cells were stimulated with EGF for 30 min (left) or HRG for the indicated times (right). Mitochondrial lysates were
subjected to immunoblot analysis with anti-MUC1 C-ter and anti-HSP60. Intensity of the signals was determined by densitometric scanning.
the 20–25 kDa MUC1 C-ter in both the cell membrane and component of the translocase of the outer membrane of mito-
chondria (TOM) (Iwahashi et al., 1997). As shown previouslymitochondria. The DF3E and ECD1 antibodies react selectively
with the HCT116/MUC1 and not the HCT116/vector cells (data (Gotow et al., 2000), Tom20 levels were substantially decreased
by trypsin treatment (Figure 2B, left). By contrast, trypsin hadnot shown). These results suggest that the 17 and 15 kDa frag-
ments represent MUC1 C-ter cleavage products without certain no effect on expression of the mitochondrial inner membrane
protein Tim23 (Figure 2B, left). To determine whether MUC1ECD sequences (Figure 2A). As controls, MUC1 N-ter expres-
sion was detectable only in the cell membrane fraction, and C-ter is integrated into mitochondrial membrane, the purified
mitochondria were incubated in alkaline sodium carbonate. TheHSP60 expression was restricted to the mitochondrial fraction
(Figure 2A). Moreover, as shown in Figure 1D, there was no extract was centrifuged, and the supernatant (luminal and pe-
ripheral proteins) and the pellet (integral membrane proteins)detectable contamination of the mitochondrial fraction with
IB, PCNA, or calreticulin (data not shown). To further assess were analyzed by immunoblotting. The results show that MUC1
C-ter is detectable in the pellet fraction and not the supernatantlocalization of MUC1 C-ter in mitochondria, we digested purified
mitochondria with trypsin. Treatment with trypsin at concentra- (Figure 2B, right). Similar results were obtained for Tom20 and
Tim23 (Figure 2B, right). As a control, the matrix HSP60 proteintions of 50 and 100 g/ml had little if any effect on MUC1 C-ter
as analyzed by immunoblotting with the Ab5, DF3E, and ECD1 was readily solubilized by alkaline sodium carbonate treatment
(Figure 2B, right). These results indicate that mitochondrialantibodies (Figure 2B, left). As a marker protein of the mitochon-
drial outer membrane, the control and trypsin-treated mitochon- MUC1 C-ter is an integral membrane protein. To extend these
findings, we expressed MUC1 C-ter with a GFP tag at the Ndria were immunoblotted with an antibody against Tom20, a
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terminus and assessed mitochondrial localization. Immunoblot and HCT116/MUC1(Y46F), cells (Figure 3C). Smac/DIABLO is
a mitochondrial protein that induces caspase-dependent cellanalysis of mitochondrial lysates with anti-GFP and anti-MUC1
C-ter confirmed mitochondrial targeting of the GFP-tagged death by interacting with inhibitor of apoptosis proteins (IAPs)
and blocking their caspase inhibitory activity (Du et al., 2000;MUC1 C-ter fusion protein (Figure 2C, upper panels). As con-
trols, expression of the platelet-derived growth factor receptor Verhagen et al., 2000). To determine if MUC1 attenuates release
of Smac/DIABLO, HCT116/vector, HCT116/MUC1, and HCT116/(PDGFR) and HSP60 was restricted to the cell membrane and
mitochondrial fractions, respectively (Figure 2C, upper panels). MUC1(Y46F) cells were treated with CDDP for 24, 48, and 72
hr, and cytosolic lysates were subjected to immunoblot analysis.The results of confocal studies also demonstrate colocalization
of GFP-MUC1 C-ter with MitoTracker (Figure 2C, lower panels). The results demonstrate that, like cytochrome c, release of
Smac/DIABLO is attenuated in HCT116/MUC1, as comparedThe transfection efficiency of HCT116 cells is25% under these
experimental conditions (Ren et al., 2002). Shown is one to HCT116/vector and HCT116/MUC1(Y46F) cells (Figure 3D).
In addition, MUC1 attenuated release of the mitochondrial cas-HCT116 cell transfected with GFP-MUC1 C-ter surrounded by
three cells not expressing the vector (Figure 2C, lower panels). pase-independent death effector apoptosis-inducing factor
(AIF) (Susin et al., 1999) as compared to that in cells expressingOf note, the GFP-MUC1 C-ter is devoid of a signal sequence
and was not detectable at the cell membrane (Figure 2C). As a the vector or MUC1(Y46F) (Figure 3D). CDDP treatment of
HCT116/vector and HCT116/MUC1(Y46F) cells for 72 hr wascontrol, the prominent pattern of mitochondrial localization was
not apparent when expressing GFP alone (data not shown). associated with 90% cell death and decreases in the -actin
signals used as a control for loading (Figure 3D). By contrast,These findings collectively demonstrate that MUC1 C-ter local-
izes to mitochondria. MUC1 C-ter is targeted to the nucleus treatment of HCT116/MUC1 cells with CDDP for 72 hr was
associated with cessation of cell growth and 
30% cell death.with -catenin in cells stimulated with EGF (Li et al., 2001b,
2003c). Stimulation of HCT116/MUC1 or HCT116/MUC1(Y46F) These findings indicate that MUC1 C-ter attenuates DNA dam-
age-induced activation of the intrinsic apoptotic pathway.cells with EGF, however, had little effect on mitochondrial tar-
geting of MUC1 C-ter (Figure 2D, left). In contrast to EGF, HRG
activates ErbB2 in the response of epithelial cells to stress MUC1 blocks DNA damage- and
TRAIL-induced apoptosis(Vermeer et al., 2003) and targets MUC1 C-ter to the nucleolus
(Li et al., 2003c). Significantly, HRG treatment for 0.5 hr was To determine if MUC1 affects the induction of apoptosis by
CDDP, cells were analyzed for sub-G1 DNA content. Treatmentassociated with a 2.3-fold increase in localization of MUC1 C-ter
to mitochondria, and this response persisted through 3 hr (Fig- of HCT116/vector cells with CDDP for 24 hr was associated
with approximately 40% apoptosis (Figure 4A). Significantly,ure 2D, right). Moreover, HRG had little effect on mitochondrial
localization of MUC1(Y46F) C-ter (Figure 2D, right). Similar re- CDDP-induced apoptosis was attenuated in HCT116/MUC1 but
not in HCT116/MUC1(Y46F) cells (Figure 4A). The attenuationsults were obtained in three separate experiments. In addition,
there was no detectable -catenin or -catenin in the mitochon- of apoptosis by MUC1 as determined from cells with sub-G1
DNA content was confirmed when using TUNEL staining as andrial fractions from control or HRG-stimulated cells (data not
shown). These findings indicate that targeting of MUC1 to mito- alternative method (data not shown). In addition, similar results
were obtained in multiple experiments with the separately iso-chondria is regulated, at least in part, by HRG-induced signaling
and that the Y46F mutation attenuates this response. lated HCT116 cell clones (Figure 4B). Expression of wild-type
MUC1 but not the MUC1(Y46F) mutant also blocked apoptosis
induced by the genotoxic agent etoposide (Figure 4C). Stimula-MUC1 attenuates cytochrome c release
and caspase-3 activation tion of cell surface death receptors with TNF- or the TNF-
related apoptosis-inducing factor TRAIL is associated with acti-Treatment of cells with DNA-damaging agents is associated
with release of mitochondrial cytochrome c and activation of vation of the extrinsic apoptotic pathway. To determine if MUC1
affects death receptor-induced apoptosis, HCT116 cells werethe intrinsic apoptotic pathway. To determine if MUC1 C-ter
affects cytochrome c release, the HCT116 transfectants were treated with TNF-. In concert with previous work (Tsuchida et
al., 1995), TNF- alone failed to induce apoptosis of HCT116/treated with cisplatin (CDDP). Treatment of HCT116/vector cells
with CDDP was associated with increased levels of cytosolic vector cells (data not shown). However, treatment with TNF-
in the presence of cycloheximide (CHX) was associated withcytochrome c (Figure 3A). Notably, expression of MUC1 signifi-
cantly attenuated the release of cytochrome c (Figure 3A). By induction of HCT116/vector cell apoptosis (Figure 4D). Similar
results were obtained when HCT116/MUC1 and HCT116/MU-contrast, expression of MUC1(Y46F) was ineffective in blocking
CDDP-induced cytochrome c release (Figure 3A). Similar results C1(Y46F) cells were treated with TNF- and CHX (Figure 4D),
indicating that MUC1 has no effect on TNF-CHX-inducedwere obtained in the other separately isolated B clones (data not
shown). Release of cytochrome c in the response to genotoxic apoptosis. By contrast, TRAIL was effective in inducing apopto-
sis of HCT116/vector cells without adding CHX and, importantly,stress is associated with activation of caspase-3 and cleavage
of PKC (Emoto et al., 1995). To assess the effects of MUC1 MUC1 but not MUC1(Y46F) attenuated this response (Figure
4E). Moreover, when HCT116/MUC1 cells were treated withon caspase-3 activation, CDDP-treated cells were analyzed for
cleavage of pro-caspase-3. The results demonstrate that, com- TRAILCHX, MUC1 was ineffective in attenuating TRAIL-
induced apoptosis (Figure 4E). Of note, CHX had no apparentpared to HCT116/vector cells, MUC1 attenuates CDDP-induced
activation of caspase-3 (Figure 3B). Cleavage of pro-caspase-3 effect on expression of MUC1 C-ter (data not shown). These
findings indicate that (1) MUC1 attenuates apoptosis inducedin CDDP-treated HCT116/MUC1(Y46F) cells was similar to that
in HCT116/vector cells (Figure 3B). In concert with these results, by activation of the intrinsic pathway, and (2) MUC1 attenuates
TRAIL-induced apoptosis by a mechanism that may be medi-caspase-3-mediated cleavage of PKC was attenuated in
CDDP-treated HCT116/MUC1, as compared to HCT116/vector ated by a short-lived protein.
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Figure 3. MUC1 attenuates CDDP-induced activation of the intrinsic mitochondrial apoptotic pathway
A: The indicated cells were treated with 100 M CDDP for 8 and 12 hr. Cytosolic lysates were analyzed by immunoblotting with anti-cytochrome c and
anti--actin.
B and C: The indicated cells were treated with 100 M CDDP for 8 and 24 hr. Cell lysates were analyzed by immunoblotting with anti-caspase-3 (B) or anti-
PKC (C) and anti--actin.
D: The indicated cells were treated with 100 M CDDP for 24, 48, and 72 hr. Cytosolic lysates were analyzed by immunoblotting with the indicated antibodies.
Diverse carcinomas express the MUC1 C-ter Downregulation of MUC1 sensitizes carcinoma cells
to apoptosis induced by genotoxic agentsin mitochondria
To determine if other carcinomas exhibit mitochondrial localiza- To assess the effects of endogenous MUC1 expression on sen-
sitivity of human carcinoma cells to genotoxic agents, wetion of the MUC1 C-ter, we first performed confocal immuno-
fluorescence studies on human SW480 colon carcinoma cells knocked down MUC1 with small interfering RNA (siRNA) du-
plexes. Exposure of A549 lung carcinoma cells to MUC1siRNAstably transfected to express an empty vector or MUC1. SW480
cells transfected with the empty vector expressed a low level was associated with downregulation of MUC1 expression (Fig-
ure 6A). As a control, there was no detectable downregulationof MUC1 and exhibited little if any MUC1 C-ter in mitochondria
(Figure 5A). By comparison, SW480/MUC1 cells exhibited sub- of MUC1 in A549 cells exposed to a control siRNA (CsiRNA)
(Figure 6A). A549 cells exposed to mock conditions, MUC1-stantially higher levels of MUC1 expression and clear colocaliza-
tion of MUC1 C-ter with MitoTracker (Figure 5A). To extend siRNA or CsiRNA, were then analyzed for annexin V staining
and sub-G1 DNA. As determined by annexin V staining, A549these observations to carcinomas that endogenously express
MUC1, we performed similar studies on human lung and breast cells exposed to CsiRNA or MUC1siRNA exhibited no significant
increase in apoptosis compared to mock conditions (Figure 6B).cancer cells. There was no detectable MUC1 N-ter in mitochon-
dria of A549 lung carcinoma cells (data not shown). However, Importantly, the A549 cells exposed to MUC1siRNA responded
to CDDP with an increase in apoptosis compared to that ob-as shown for the MUC1 transfectants, the MUC1 C-ter was
detectable in mitochondria (Figure 5B). Similar results were ob- tained with cells exposed to mock conditions or CsiRNA (Figure
6B). Similar results were obtained in multiple experiments andtained with T-47D (Figure 5C) and ZR-75-1 (Figure 5D) breast
carcinoma cells. These findings indicate that the MUC1 C-ter by analysis for sub-G1 DNA (Figure 6C and data not shown).
To extend these observations to another cell type, we gener-localizes to mitochondria in both MUC1 transfectants and carci-
nomas that endogenously express MUC1. ated a retrovirus expressing MUC1siRNA. Infection of ZR-75-1
168 CANCER CELL : FEBRUARY 2004
A R T I C L E
Figure 4. MUC1 attenuates DNA damage- and TRAIL-induced apoptosis
A: The indicated cells were treated with 100 M CDDP for 24 hr and then analyzed for sub-G1 DNA.
B: Clones A and B of the indicated cells were left untreated (open bars) or treated with 100 M CDDP for 24 hr (solid bars).
C: Clones A and B of the indicated cells were left untreated (open bars) or treated with 70 M etoposide for 48 hr (solid bars).
D: Clones A and B of the indicated cells were left untreated (open bars) or treated with 20 ng/ml TNF- and 10 g/ml CHX for 12 hr (closed bars). The
results are presented as the percentage apoptosis (mean  SD of three independent experiments) as determined by analysis of sub-G1 DNA.
E: The indicated cells were left untreated (open bars) or treated with 100 ng/ml TRAIL for 14 hr (closed bars) (left). HCT116/MUC1 cells were treated with
100 ng/ml TRAIL and/or 10 g/ml CHX as indicated for 14 hr (right). The results are presented as the percentage apoptosis (mean  SD of three experiments)
as determined by analysis of sub-G1 DNA.
breast carcinoma cells with the MUC1siRNA retrovirus and se- sis (Figure 7C). Treatment of ZR-75-1/vector cells with CDDP
lection in G418 was associated with stable downregulation of was associated with the induction of 25% apoptosis (Figure
MUC1 expression (Figure 7A). As a control, stable transduction 7C). Significantly, treatment of ZR-75-1/MUC1siRNA cells with
of ZR-75-1 cells with the empty retrovirus had no effect on CDDP resulted in over 60% apoptosis (Figure 7C). The ZR-
MUC1 expression (Figure 7A). Release of mitochondrial apopto- 75-1 cells were also treated with different concentrations of
genic factors is associated with loss of the mitochondrial trans- etoposide. The results show that sensitivity to 10 and 50 M
membrane potential (m) (Arnoult et al., 2003). CDDP-treated etoposide was increased substantially by knocking down MUC1
ZR-75-1/vector cells exhibited little if any decrease in m expression (Figure 7D). These findings and those in A549 cells
(Figure 7B). By contrast, CDDP treatment of ZR-75-1/MUC1s- indicate that knocking down MUC1 expression increases sensi-
iRNA cells was associated with a clear loss of m (Figure
tivity to genotoxic agents.7B). In concert with these findings, cytochrome c release was
attenuated in CDDP-treated ZR-75-1/vector, as compared to
MUC1 confers resistance to genotoxic agents in vivoZR-75-1/MUC1siRNA, cells (Figure 7B). In the absence of expo-
To determine if MUC1 expression affects chemosensitivity insure to a cytotoxic agent, ZR-75-1 cells expressing the empty
retroviral vector or MUC1siRNA exhibited less than 5% apopto- vivo, HCT116/vector and HCT116/MUC1 cells were injected
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Discussion
MUC1 localizes to mitochondria
Recent work has indicated that MUC1 C-ter functions as a
transducer of signals from activated ErbB receptor tyrosine ki-
nases and the Wnt pathway to the nucleus (Li et al., 2003c). In
the present studies, confocal microscopy showed that MUC1
C-ter also localizes to mitochondria. Subcellular fractionation
studies confirmed mitochondrial targeting of MUC1 C-ter and
not MUC1 N-ter. Immunoblot analysis of subcellular fractions
showed that mitochondrial MUC1 C-ter is similar to MUC1 C-ter
at the cell membrane. The results indicate that mitochondrial
MUC1 C-ter (20–25 kDa) includes both ECD and CD sequences
and that the 17/15 kDa fragments may represent MUC1 C-ter
cleavage products. Cell fractionation and confocal microscopy
studies of GFP-tagged MUC1 C-ter further confirmed localiza-
tion of MUC1 C-ter to mitochondria. Our results also indicate
that MUC1 C-ter is expressed in mitochondria as an integral
membrane protein. MUC1 C-ter most likely localizes to the mito-
chondrial outer membrane (MOM) based on the lack of a readily
identifiable mitochondrial targeting sequence and a functional
role in attenuating activation of the intrinsic apoptotic pathway.
Little is known, however, about how proteins are targeted to the
MOM and then integrated in mitochondrial membranes (Mihara,
2000; Rapaport, 2003). The N terminus of Tom20 is anchored
in the mitochondrial outer membrane and, as such, the C termi-
nus is susceptible to protease digestion. Other proteins, such
as Bcl-2 and Bcl-xL, are anchored to the MOM by their C termini.
Conversely, Tom40 is tightly embedded in the MOM and is not
accessible to proteases (Suzuki et al., 2000). The demonstration
that MUC1 C-ter is also not susceptible to trypsin digestion
indicates that MUC1 C-ter may be embedded in the MOM. Our
data, however, do not exclude the possibility that MUC1 C-ter
may associate with the mitochondrial inner membrane. In this
Figure 5. MUC1 C-ter localizes to mitochondria of diverse carcinoma cells
context, Bcl-2 has been detected in both the mitochondrial
A: SW480 carcinoma cells stably transfected to express an empty vector outer and inner membranes (Gotow et al., 2000).or MUC1 were incubated with anti-MUC1 C-ter and then a FITC-conjugated
The present studies further demonstrate that treatment ofsecondary antibody. Mitochondria were stained with MitoTracker Red. Nu-
clei were stained with TO-PRO-3. Scale bars represent 20 m. cells with HRG but not EGF is associated with increased tar-
B–D: A549 lung (B), T-47D breast (C), and ZR-75-1 breast (D) carcinoma cells geting of MUC1 C-ter to mitochondria. Previous work using ZR-
were analyzed by staining with anti-MUC1 C-ter, MitoTracker Red, and TO- 75-1 and HCT116/MUC1 cells has shown that HRG stimulates
PRO-3. Scale bars represent 10 m (B) or 20 m (C and D).
binding of MUC1 C-ter to -catenin and that MUC1 C-ter func-
tions as a shuttle for nuclear targeting of -catenin (Li et al.,
2003c). The present results indicate that MUC1 C-ter is not
complexed with -catenin when targeted into mitochondria. Insubcutaneously into the flanks of nude mice. Growth of the
this regard, we have not found -catenin in mitochondria of
HCT116/MUC1 cells was similar to that found for the HCT116/
HRG-stimulated ZR-75-1 or HCT116/MUC1 cells (data not
vector cells (Figure 8A). CDDP treatment of mice injected with shown). These results support a model in which the discrimina-
the HCT116/vector cells was associated with a significant inhibi- tion between nuclear or mitochondrial localization of MUC1
tion of tumor growth (Figure 8A). Notably, however, treatment C-ter is determined by HRG-induced activation of distinct sig-
of the HCT116/MUC1 tumors with CDDP resulted in little if any naling pathways. The results also demonstrate that constitutive
effect (Figure 8A). To determine if knocking down MUC1 affects and HRG-induced mitochondrial targeting of MUC1 C-ter are
chemosensitivity, we injected mice with ZR-75-1 cells stably attenuated by the Y46F mutation. This finding is consistent, at
expressing the empty retroviral vector or MUC1siRNA. Growth least in part, with the involvement of a tyrosine kinase that is
of the ZR-75-1/MUC1siRNA tumors was somewhat slowed activated and phosphorylates Y-46 in the HRG response. c-Src
compared to that found for ZR-75-1/vector cells (Figure 8B). is activated by HRG (Belsches-Jablonski et al., 2001; Vadlamudi
Treatment with CDDP was associated with a partial slowing of et al., 2003) and phosphorylates MUC1 on Y-46 (Li et al., 2001a).
ZR-75-1/vector tumor growth (Figure 8B). In contrast, the ZR- Thus, c-Src or other tyrosine kinases that are activated by HRG
75-1/MUC1siRNA tumors were considerably more sensitive to may contribute to mitochondrial targeting of MUC1 C-ter. Addi-
CDDP treatment (Figure 8B). These findings indicate that MUC1 tional work has shown that MUC1 C-ter forms a complex with
expression contributes to CDDP resistance of carcinoma cells the cytosolic chaperones HSP70 and HSP90 and that these
interactions are attenuated by the Y46F mutation (unpublishedin in vivo tumor models.
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Figure 6. Transient downregulation of MUC1 expression sensitizes A549 carcinoma cells to CDDP-induced apoptosis
A: A549 cells were treated with CsiRNA or MUC1siRNA and harvested 72 hr after transfection. Lysates were analyzed by immunoblotting with anti-MUC1
N-ter and anti--actin.
B: A549 cells were left untransfected (MOCK) or transfected with MUC1siRNA or CsiRNA, incubated for 72 hr, and then treated with 10 M of CDDP for 48
hr. Cells were stained with FITC-conjugated annexin V and analyzed by flow cytometry.
C: The results for MOCK (open bars), MUC1siRNA transfected (solid bars), or CsiRNA transfected (hatched bars) cells are expressed as the percentage
apoptosis (mean  SD of three independent experiments).
data). HSP70 and HSP90 function in the delivery of proteins our studies was generated without a signal sequence and was
not detectable at the cell surface. Thus, the detection of GFP-to the mitochondrial import receptor Tom70 and thus may be
responsible for targeting MUC1 C-ter to the MOM (Truscott et MUC1 C-ter in mitochondria indicates that MUC1 C-ter can be
targeted into mitochondria without prior localization to the cellal., 2003; Young et al., 2003). The GFP-MUC1 C-ter used in
Figure 7. Stable downregulation of MUC1 sensitizes ZR-75-1 cells to CDDP- and etoposide-induced apoptosis
A: ZR-75-1 cells were infected with a control retroviral vector or one expressing MUC1siRNA. Stable transfectants were selected in the presence of G418.
Cells were incubated with anti-MUC1 N-ter (open patterns) or control mouse IgG (closed patterns) and analyzed for immunofluorescence by flow cytometry
(left). Lysates were analyzed by immunoblotting with the indicated antibodies (right panels).
B: ZR-75-1/vector and ZR-75-1/MUC1siRNA cells were incubated with DiOC6[3] and then left untreated (Control) or exposed to 25 M CDDP for 48 hr.
Mitochondrial transmembrane potential was assessed by flow cytometry (upper panels). Cytosolic lysates were analyzed by immunoblotting with the
indicated antibodies (lower panels).
C and D: ZR-75-1/vector (open bars) and ZR-75-1/MUC1siRNA (solid bars) cells were treated with 25 M CDDP for 72 hr (C) or with 10 and 50 M etoposide
for 72 hr (D). Cells were analyzed for sub-G1 DNA. The results are presented as the percentage apoptosis (mean  SD of three independent experiments).
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cer agents is of potential importance. The present results further
demonstrate that MUC1 expression is associated with attenua-
tion of CDDP-induced release of mitochondrial cytochrome c,
Smac/DIABLO, and AIF. In addition, the MUC1(Y46F) mutant
was less effective than MUC1 in attenuating CDDP-induced
release of these apoptogenic proteins. In concert with these
findings, MUC1 but not MUC1(Y46F) was also effective in atten-
uating CDDP-induced activation of caspase-3 and cleavage of
PKC. These findings were not restricted to CDDP, since MUC1
also attenuated activation of the intrinsic mitochondrial pathway
by etoposide (data not shown). Moreover, the results are not
attributable to clonal variation, because independently selected
HCT116/MUC1 clones exhibited the same resistant phenotype.
Overexpression of MUC1 in rat 3Y1 cells is associated with
increases in phospho-Bad and Bcl-xL levels (unpublished data).
The finding, however, that HCT116/MUC1 cells do not express
increased levels of phospho-Bad or of the Bcl-xL/Bcl-2 proteins
(data not shown) indicates that MUC1 C-ter attenuates DNA
damage-induced release of apoptogenic mitochondrial ef-
fectors by other mechanisms. In this regard, the present results
indicate that MUC1 attenuates loss of m in the response to
DNA damage. Release of mitochondrial apoptogenic factors
can occur in part without changes in m; however, complete
release of cytochrome c and Smac/DIABLO has been associ-
ated with loss of m (Arnoult et al., 2003). Thus, MUC1 C-ter
may attenuate mitochondrial release of apoptogenic factors by
stabilizing them in response to stress. Nuclear MUC1 C-ter
may also contribute to attenuation of proapoptotic signals that
are activated by DNA damage. To further define the mechanistic
effects of MUC1 C-ter on the intrinsic pathway, studies are
underway to determine whether MUC1 C-ter regulates proapo-
ptotic proteins that induce loss of m.
Stimulation of TNF-receptor-1 (TNF-R1) or the TRAIL recep-Figure 8. MUC1 confers resistance to CDDP treatment in vivo
tors (R1 and R2) activates caspase-8 and thereby the extrinsicA: HCT116/vector (,) or HCT116/MUC1 (,) cells (1	 106) were injected
apoptotic pathway. Caspase-8-mediated cleavage of Bid alsosubcutaneously into the posterior flanks of nude mice.
B: ZR-75-1/vector (, ) or ZR-75-1/MUC1siRNA (, ) cells (1 	 107) were links death receptor signaling to the mitochondrial pathway by
injected into nude mice that had been pretreated with -estradiol. The inducing the release of cytochrome c and Smac/DIABLO (Du
mice were treated as indicated (arrows) with intraperitoneal injections of et al., 2000; Li et al., 1998a; Luo et al., 1998; Verhagen et al.,PBS (, ) or 7 mg/kg CDDP (, ). Tumor volumes were calculated from
2000). In this context, death receptor-induced apoptosis of typebidimensional measurements at the indicated times. The results are ex-
pressed as the tumor volume (mean  SD) of 4–8 mice per group. II cells is dependent on the mitochondrial pathway (Scaffidi et
al., 1998). Based on the finding that MUC1 attenuates DNA
damage-induced apoptosis by downregulating mitochondrial
signaling, we asked if MUC1 also affects stimulation of the
membrane. MUC1 C-ter (no signal sequence) may be expressed extrinsic pathway. Treatment of HCT116/vector cells with TNF-
by alternate splicing of MUC1 transcripts and thereby targeted alone resulted in no detectable apoptosis. However, in concert
directly to mitochondria. Alternatively, the results obtained with with reports in other cell types (Tsuchida et al., 1995), HCT116/
GFP-MUC1 C-ter may reflect a physiologic or stress-induced vector cells exhibited an apoptotic response when treated with
mechanism in which, after processing in the ER, MUC1 C-ter TNF- and CHX. The results show that MUC1 has no apparent
is released into the cytosol and transported to mitochondria. In effect on TNF-CHX-induced apoptosis. By contrast, apopto-
support of such mechanisms, the c-Abl kinase localizes to the sis of HCT116/vector cells was induced by TRAIL in the absence
ER and is trafficked to mitochondria in the response to stress of CHX. Moreover, MUC1 and not MUC1(Y46F) attenuated
(Ito et al., 2001). Additional studies are ongoing to more precisely TRAIL-induced apoptosis, indicating that MUC1 C-ter downreg-
define the signals responsible for both the targeting and inser- ulates mitochondrial amplification of TRAIL death signaling. Im-
tion of MUC1 C-ter as an integral mitochondrial membrane portantly, the attenuation of TRAIL-induced apoptosis by MUC1
protein. was reversed by adding CHX. These results indicate that MUC1-
mediated downregulation of TRAIL-induced apoptosis is con-
MUC1 attenuates the intrinsic apoptotic pathway ferred by the synthesis of a short-lived protein (Munshi et al.,
Genotoxic agents that are used in cancer treatment often induce 2001; Thakkar et al., 2001; Wajant et al., 2000). The use of CHX
apoptosis by activation of the mitochondrial pathway (Herr and with TNF-may also explain why MUC1 had no effect on TNF-
Debatin, 2001; Kroemer and Reed, 2000). Thus, the identifica- CHX-induced apoptosis. These findings indicate that attenua-
tion of the intrinsic pathway by mitochondrial localization oftion of antiapoptotic proteins that confer resistance to antican-
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inactivated fetal bovine serum, 100 units/ml penicillin, 100 g/ml streptomy-MUC1 C-ter may affect death receptor-induced apoptosis.
cin, and 2 mM L-glutamine. Human A549 lung, T-47D breast, and ZR-75-1However, the results do not exclude the possibility that MUC1
breast carcinoma cells (ATCC) were grown in RPMI 1640 medium containingmay downregulate death receptor signaling by other mecha-
10% heat-inactivated fetal bovine serum, antibiotics, and L-glutamine. Insu-
nisms. lin (10 ng/ml; Life Technologies, Rockville, MD) was also added to cultures
of the T-47D cells. Cells were treated with EGF (10 ng/ml; Calbiochem-
Have human tumors exploited MUC1 as an otherwise Novabiochem, San Diego, CA), HRG (20 ng/ml; Calbiochem-Novabiochem),
cisplatin (CDDP; Sigma), etoposide (Sigma), rhTNF- (Promega, Madison,physiologic mechanism to attenuate
WI), CHX (Sigma), or rhTRAIL (100 ng/ml; Calbiochem-Novabiochem).stress-induced apoptosis?
Stable expression of MUC1 in the MUC1-negative HCT116 cells
Cell transfectionsrepresents one approach to assess the effects of MUC1 on
HCT116 cells were transfected with pIRES-puro2, pIRESpuro2-MUC1, or
chemosensitivity. We reasoned, however, that downregulating pIRES-puro2-MUC1(Y46F), as described (Li et al., 2001b). SW480 cells were
MUC1 in carcinoma cells that endogenously overexpress this transfected with pIRES-puro2 or pIRES-puro2-MUC1. Stable transfectants
oncoprotein might be equally informative. MUC1siRNA was thus were selected in the presence of 0.4g/ml puromycin (Calbiochem-Novabio-
used to knock down MUC1 expression in A549 lung and ZR- chem, San Diego, CA). Two independent transfections were performed for
each vector. Single cell clones were isolated by limiting dilution and ex-75-1 breast cancer cells. The results demonstrate that transient
panded for analysis. In other studies, HCT116 cells were transiently trans-downregulation of MUC1 expression in A549 cells is associated
fected with the pEGFP-C1 vector (Clontech) in which MUC1 C-ter was clonedwith increased sensitivity to CDDP-induced apoptosis. Stable
downstream to sequences encoding the green fluorescence protein (GFP).downregulation of MUC1 in ZR-75-1 cells also resulted in an
increased apoptotic response to CDDP treatment in vitro. More- Immunoblot analysis
over, the demonstration that MUC1 downregulation potentiates Lysates were prepared from subconfluent cells as described (Li et al., 2001a).
apoptosis induced by etoposide indicates that MUC1 expres- Equal amounts of protein were separated by SDS-PAGE and transferred to
nitrocellulose membranes. The immunoblots were probed with anti-MUC1sion attenuates the apoptotic response to diverse genotoxic
N-ter (DF3) (Kufe et al., 1984), anti-MUC1 C-ter (Ab5; Neomarkers, Fremont,agents in vitro. Importantly, stable downregulation of MUC1
CA), anti-MUC1 C-ter (rabbit polyclonal DF3E) (Li et al., 2001a), anti-MUC1increased the sensitivity of ZR-75-1 tumors to CDDP treatment.
C-ter (monoclonal ECD1; generated against the MUC1 ECD), anti--actinConversely, MUC1 expression in HCT116 cells conferred in
(Sigma), anti-HSP60 (Stressgen Biotechnologies, Victoria, BC, Canada), anti-
vivo resistance to CDDP treatment. These findings suggest that PCNA (Calbiochem-Novabiochem, San Diego, CA), anti-IB (Santa Cruz
MUC1 may contribute to resistance of human tumors to geno- Biotechnology, Santa Cruz, CA), anti-calreticulin (Stressgen Biotechnolog-
toxic anticancer agents. ies, Victoria, BC, Canada), anti-PDGFR (Santa Cruz Biotechnology), anti-
Tom20 (BD PharMingen, San Diego, CA), anti-Tim23 (BD PharMingen), anti-Mucins represent a defensive physical barrier to environ-
cytochrome c (BD PharMingen), anti-caspase-3 (BD PharMingen), anti-PKCmental stress and may function in transducing signals that pro-
(Santa Cruz Biotechnology), anti-Smac/DIABLO (Medical & Biological Labo-tect the epithelium from damage. Mechanical or toxic damage
ratories, Ltd., Japan), or anti-AIP (Santa Cruz Biotechnology). The immunocom-to epithelial cells is associated with disruption of tight junctions
plexes were detected with horseradish peroxidase-conjugated secondary
between neighboring cells, loss of polarity, and activation of a antibodies and enhanced chemiluminescence (ECL, Amersham Biosciences,
repair program (Vermeer et al., 2003). Stimulation of ErbB2 by Piscataway, NJ). Intensity of the signals was determined by densitometric
HRG contributes to this repair by promoting cell division and scanning.
thereby replacement of damaged cells (Vermeer et al., 2003).
Flow cytometryOur findings that HRG stimulation also induces both nuclear (Li
Cells were incubated with anti-MUC1 N-ter or control mouse IgG for 1 hret al., 2003c) and mitochondrial targeting of MUC1 C-ter sug-
at 4C, washed, incubated with goat anti-mouse Ig fluorescein-conjugatedgest that MUC1 may play a role in the repair of epithelial integrity.
antibody (Jackson Immunoresearch Laboratories, West Grove, PA), and then
The epithelial stress response is transiently associated with loss fixed in 2% formaldehyde/PBS. Reactivity was detected by FACScan.
of polarity (Vermeer et al., 2003). With transformation and transi-
tion to a mesenchymal phenotype, epithelial cells lose the capa- Confocal microscopy
Cells cultured on coverslips were incubated in Dulbecco’s modified Eagle’s/bility to reverse loss of polarity. Thus, in the HRG-induced stress
F12 medium containing 100 nM MitoTracker Red CMXRos (Molecularresponse of normal epithelial cells, nuclear and/or mitochondrial
Probes, Eugene, OR) for 20 min at 37C. After staining, the cells were washedMUC1 could transiently protect against apoptosis following in-
with fresh growth medium, prefixed in 3.7% formaldehyde/growth mediumjury. Conversely, irreversible nuclear and/or mitochondrial tar-
for 15 min at 37C, washed with PBS, permeabilized in PBS containing 0.2%
geting of MUC1 in carcinoma cells could confer a phenotype Triton X-100 for 5 min at 25C, washed with PBS, then postfixed in 3.7%
that is stably resistant to stress-induced apoptosis. In this re- formaldehyde/PBS for 5 min at 25C. After several washes with PBS, the
gard, our previous studies showed that MUC1 overexpression cells were blocked with 10% goat serum for 1 hr at 25C, stained with anti-
MUC1 C-ter antibody for 1.5 hr at 25C, washed with PBS, incubated withprotects cells against oxidative stress-induced apoptosis (Yin
FITC-conjugated secondary antibody (Jackson ImmunoResearch Labora-and Kufe, 2003). Moreover, the present finding that MUC1 atten-
tories, West Grove, PA) for 40 min at 25C, washed with PBS, and incubateduates the apoptotic response to DNA damaging agents is of
with 2 M TO-PRO3 (Molecular Probes) for 10 min at 25C. After mountingpotential importance to cancer treatment. Thus, what appears
the coverslips, images were captured with a LSM510 confocal microscope
to be a physiologic mechanism to protect normal epithelial cells (ZEISS) at 1024 	 1024 pixel resolution. The excitation wavelength for FITC,
against apoptosis during stress-induced repair may have been MitoTracker Red, and TO-PRO3 were 488 nm, 543 nm, and 633 nm, respec-
exploited by human tumors to survive under adverse conditions tively. Fluorescein fluorescence was captured through a 505–530 nm band-
pass filter. MitoTracker Red CMXRos fluorescence was collected throughand in response to anticancer agents.
a 560–615 nm band-pass filter. TO-PRO3 staining was visualized through
a 650 nm long-pass filter.Experimental procedures
Subcellular fractionationCell culture
Purified mitochondria and cytoplasmic lysates were prepared as describedHuman HCT116 and SW480 colon carcinoma cells (ATCC, Manassas, VA)
were cultured in Dulbecco’s modified Eagle’s medium/F12 with 10% heat- (Kumar et al., 2003). Cell membranes were purified from supernatants after
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sedimentation of nuclei and mitochondria as described (Kharbanda et al.,
1996). Purified mitochondria (0.4 mg protein/ml) were resuspended in 5 mM Received: August 7, 2003
HEPES (pH 7.4), 210 mM mannitol, 70 mM sucrose, and 1 mM EGTA before Revised: December 12, 2003
treatment with trypsin (Sigma) at concentrations of 50 and 100 g/ml for 20
Accepted: December 22, 2003
min at 4C. The samples were then subjected to SDS-PAGE and immunoblot-
Published: February 23, 2004ting. Purified mitochondria (0.4 mg protein/ml) were also resuspended in
0.1 M Na2CO3 (pH 11.5), incubated for 30 min at 0C, and then centrifuged References
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The supernatant and pellet were then subjected to immunoblot analysis.
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